Newborn Screening Market Forecast Trends To 2022 Grand View Research Inc.


(MENAFNEditorial)

Global newborn screening market is anticipated to exhibit substantial growth in the next seven years owing to rising incidence of newborn diseases awareness among the population base and rising need of prevention of incidences of neonatal disorders in initial phases. Furthermore technological advancements such as digital micro fluid technology sequencing technology DNA assays immunoassays hearing screen technology and pulse-oximetry screening are expected to drive growth potential over the forecast period.

For More Information on "Newborn Screening Market Research Reports" visit - http://www.grandviewresearch.com/industry-analysis/newborn-screening-market

The newborn screening market is segmented on the basis of test type product and technology. On test type basis the market is further segmented into dry blood spot test critical congenital heart disease and hearing screen test. The dry blood spot test market shares the highest market owing to sample stability and reliable results. For instance Recent FDA’s review included a study of approximately 6400 blood spot specimens from routine screening of newborns 17 of which had tested SCID positive. Technology segment includes tandem mass spectrometry DNA-assays enzymes-based assays pulse oximetry technology and electrophoresis. Tandem mass spectrometry held the largest market share in 2014 as a consequence of their ability to reduce trauma and provide early diagnosis of disorders. Product segment includes instruments and reagents & assay kits which are further divided into pulse oximetry instruments and hearing screening devices & instruments.
As of 2014 North America held the substantial market share owing to factors such as government initiatives & high awareness and rising epidemics of neonatal disorders. According to the Centres for Disease Control and Prevention approximately 40 to 100 incidences of Severe Combined Immunodeficiency (SCID) occur in United States yearly. Asia Pacific region is anticipated to be the fastest growing market primarily owing to the factors such as increasing disposable income enhancing healthcare infrastructure rising financial support from foreign organisations and rising opportunities for new market players.

Request TOC of “Newborn Screening Market Research Reports" visit - http://www.grandviewresearch.com/industry-analysis/newborn-screening-market/request-toc

The major players of this market are Covidien PLC Bio-Rad Laboratories Masimo Corporation GE Life Sciences Agilent Technologies Waters Corporation AB SCIEX Trivitron Healthcare and PerkinElmer Inc. These companies employ product diversification strategies and comprehensive technician training systems to enhance their market position. For Instance PerkinElmer launched first genetic disorder screening system in China. These companies also involve in intensive marketing of the clinically approved products in order to expand their market share. For Example U.S. FDA approved marketing of EnLite’S Neonatal TREC Kit which is the first screening test allowed to be marketed by FDA for Severe Combined Immunodeficiency (SCID) in newborns.

Access full report @ https://www.linkedin.com/pulse/newborn-screening-market-analysis-share-2022-grand-view-pawar

About Grand View Research
Grand View Research Inc. is a U.S. based market research and consulting company registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports customized research reports and consulting services. To help clients make informed business decisions the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology chemicals materials healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist U.S.A.
Grand View Research Inc.
United States
Phone:  1-415-349-0058
Toll Free:  1-888-202-9519
Email:  sales@grandviewresearch.com
Website: Grand View Research
Blog Site: http://www.divog.org/

 


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.